Reversing neurodegeneration.
Restoring function already lost is the standard I want future evidence to face.
Evolution is too slow to save anyone now alive.
Human biology fails on a schedule set by inheritance, not by choice. I think that schedule deserves deliberate, supervised, evidence-bound work on a human timescale. Novel Biotech is where I do that work in public, starting from questions rather than a product.
- CONCEPT STUDY
- RESEARCH ONLY
- NO HUMAN TESTING
- NOT AVAILABLE
- NO DEVELOPMENT PROGRAM EXISTS
- Stage
- concept
- Entity
- none
- People
- one, the founder
- Program
- none selected
- Human testing
- none
- Applications
- see Join for delivery status
Current public state. No row implies readiness or authorization.
What I intend to do, in order.
None of this has started. It is the sequence I would follow if the evidence and the people allow it. Nothing is in development.
- THERAPEUTICS FIRSTLearn regulated development properly.
Medicines before devices, under qualified scientific, clinical, regulatory, safety, legal, and engineering supervision rather than around it.
- ONE RARE DISEASEStart with a rigorously selected problem.
No indication has been chosen. Patient benefit, safety, evidence quality, consent, access, and governance outrank speed, cost, and prestige.
- THEN THE HARD AIMSNeurodegeneration, aging, and eventually implantable systems.
Reversing lost function and slowing aging are co-equal ambitions. Implantable and cybernetic systems are later possibilities, kept as concept studies until then.
hypothesis — untested
Deliberate intervention can outrun inherited biological change.
That is my hypothesis. It is falsifiable, it has not been tested here, and nothing on this site is a result.
Materially slowing biological aging.
Measured in health retained, not years promised. I make no claim about anyone’s lifespan.
method — not a development plan
How the record is kept.
- Concepts
- A concept study asks one bounded question and shows the evidence for each part of it. It selects no device, architecture, or indication.
- Evidence
- Each source is listed with what it supports, the model or population it used, and what it does not show. Sources do not become Novel Biotech results.
- Acceptance
- When a record is accepted, exact files are frozen and their limits are written down. Acceptance never becomes permission to build.
CURRENT ABSENCE // FACT
There is no organization behind this yet.
No incorporated entity, staff, laboratory, funding, product, program, therapy, human testing, approvals, or customers. Recruitment is being prepared; no role exists to fill.
The record can improve without implying that a company or a development program has been chosen.